

NA-specific antibody responses are generated in naïve and vaccinated newborns following virus infection

Patrick K. Shultz^{1,2}, Kali F. Crofts^{1,2}, Beth C. Holbrook¹ and Martha A. Alexander-Miller^{1*}

¹Department of Microbiology and Immunology, Wake Forest School of Medicine, Winston-Salem, NC

²These authors contributed equally to this work.

*Corresponding author:

Dr. Martha A. Alexander-Miller
Department of Microbiology and Immunology
Wake Forest School of Medicine
575 N. Patterson Avenue
2E-018 Biotech Place
Winston-Salem, NC 27101
Phone: 336 716-5936
Email: Martha.Alexander-Miller@wakehealth.edu

Conflict of interest: The authors have declared that no conflict of interest exists.

ABSTRACT

Those under the age of 6 months are at significant risk from influenza virus infection; however, there is currently no vaccine approved for this age group. Influenza virus neuraminidase has emerged as a potential additional target for vaccine strategies. In this study, we sought to understand the ability of newborns to mount an antibody response to neuraminidase. Here we employed a nonhuman primate model given the similarities to humans in the immune system and development. We measured antibody to neuraminidase following infection with an H1N1 virus or following vaccination and challenge. Administration of an inactivated virus vaccine was not capable of eliciting detectable NA-specific antibody, even in the presence of adjuvants previously shown to increase total virus-specific IgG. However, both naïve and vaccinated newborns generated a neuraminidase-specific antibody response following virus infection. Interestingly, the presence of the vaccine-induced response did not prevent generation of systemic antibody to neuraminidase following challenge, although the respiratory response was reduced in a significant portion of newborns. These findings are the first, to our knowledge, to evaluate the newborn response to the influenza neuraminidase protein as well as the impact of previous vaccination on generation of these antibodies following virus infection.

INTRODUCTION

Neuraminidase (NA) is an influenza virus surface protein that cleaves sialic acid on the host cell surface, allowing newly formed virions to be released (1-3). In the absence of NA activity, hemagglutinin remains bound, thereby preventing virus spread. NA also functions to prevent virus aggregation by desialylating HA, increasing its infectivity (3). Finally, there is evidence that NA can contribute to viral entry through cleavage of sialic acid, allowing the virus to more efficiently penetrate the mucus layers of the respiratory tract (1,4).

There is accumulating evidence of the potential for antibody capable of inhibiting NA enzymatic activity to contribute to viral clearance and protection (5-13). NA inhibiting (NAI) antibody can be detected in most individuals, although the induction of these antibodies following infection is significantly reduced compared to HA (14). This is likely, at least in part, due to the lower amounts of NA in the virion (40-50 molecules compared to 300-400 HA molecules) (15). The reduced antibody response to NA is even more apparent following administration of the seasonal inactivated vaccine, with 1% compared to 87% of influenza-specific antibodies recognizing NA vs. HA (14). While inhibiting NA cannot prevent the host from becoming infected, it does limit virus spread. As such, antibody to NA can lessen virus-related damage in the lungs in animal studies (16) and provide protection in humans (5-12). Thus, NA-specific antibodies are an attractive target in the search for a vaccine that can provide broader recognition (13,14,17,18).

Infection with influenza virus poses a substantial threat for newborns and young infants (19-21). These individuals are highly susceptible to infection, with infants less than 6 months of age carrying a significantly increased risk for severe disease resulting in hospitalization and even death compared to older children (22,23). Influenza-associated disease is the result of severe damage and inflammation to the respiratory epithelium that can lead to pneumonia (24). The increased risk for more severe disease in young infants is the result of their naïve status combined with altered immune responsiveness in this age group (25,26). The latter is

responsible for the lack of efficacy in young infants and thus the absence of an approved influenza vaccines for infants under 6 months of age.

Increasing the ability of newborns to more effectively combat influenza virus infection or respond to NA-targeted vaccines requires a deeper understanding of the capacity of these individuals to produce these antibodies and the signals that optimally promote their generation. Newborns are challenged in the ability to mount a robust antibody response following infection or vaccination (for review see (27,28)). This is the result of multiple alterations in the immune response, including decreased dendritic cell (DC) maturation, reduced T follicular helper (Tfh) generation, and poorer upregulation of molecules contributing to B cell activation and differentiation (29-32). At present, we know little about how effectively newborns can generate a response to NA.

In the study presented here, we utilized a nonhuman primate (NHP) model to evaluate the ability of newborns to produce NA-specific antibody following vaccination and infection. This model was selected as it is the closest to humans with regard to immune development in early life and innate sensor distribution and function. The results from these studies provide novel insights into our understanding of the newborn immune response to influenza virus infection and inform strategies for developing a protective vaccine.

RESULTS

Newborn African green monkeys produce NAI antibodies following infection with

influenza A virus. The ability of newborns to mount an antibody response capable of inhibiting NA activity following infection with influenza virus has not been explored. To address this question, four newborn (6-10 days of age) NHP were inoculated with either 1×10^9 (3 animals) or 1×10^8 (1 animal) EID₅₀ of mouse-adapted influenza A virus strain (A/PR/8/34 (H1N1) (PR8). The lower dose animal was part of a dose escalation experiment during development of our infection model. As the response was similar to the animals receiving the high dose, the four newborns were pooled for analysis. Four adult animals (aged 6-9 years) were infected with 5×10^9 EID₅₀ PR8 in parallel. Blood was sampled at d14 postinfection (p.i.) and the presence of NA-specific antibodies measured. We utilized two approaches to evaluate responses to NA: 1) a cell based ELISA to quantify total IgG antibody to the NA protein (33) and 2) an Enzyme Linked Lectin Assay (ELLA) to measure antibodies with NAI activity (34). The former was important as antibodies that can bind NA in the absence of blocking enzymatic activity have been described (35).

Both newborn and adult animals had high levels of NA-specific IgG in the plasma at d14 following infection (Fig. 1A). These animals also had antibodies with readily detectable NAI activity (Fig. 1B). No significant difference in titer was detected between these groups for either NA-specific total or NAI antibody. In general there were similar trends in the two readouts (Fig. 1C), suggesting a similar portion of the NA-specific antibody present in adult and newborn animals has NAI activity. The comparable amounts of NA-specific IgG in the newborn and adult animals is in agreement with our previous analysis of total influenza-specific IgG antibody in these animals at this timepoint (36).

Given the localization of influenza virus to the lungs, we evaluated the antibody available to combat infection in this tissue. Total NA-specific (Fig. 1D) and NAI antibody (Fig. 1E) in the bronchoalveolar lavage (BAL) fluid obtained from the newborns and adults at d14 p.i. was

measured. NA-specific antibody was detected in 3 of four adult animals and all of the newborns (Fig. 1D). Antibodies with NAI activity were similarly detected (Fig. 1E). The titers for the two readouts for individual animals is shown in Figure 1F. While not statistically significant, we noted the unexpected trend of higher antibody titer to NA in newborns, which was not evident in our previous analyses of total influenza-specific IgG antibody in the respiratory tract (36). Whether the antibody response to NA at this site may be differentially regulated compared to the overall response is not clear. These data show that newborns readily generate NAI antibodies following influenza virus infection and that these important effector molecules are present in both circulation and the respiratory tract.

Vaccination with inactivated influenza virus does not result in detectable antibody that can recognize NA at 10 days following boost. Having established the ability of newborns to produce NA inhibiting antibodies following infection, we next evaluated their generation in response to vaccination. We had previously assessed the influenza virus-specific response of newborn AGM administered formalin inactivated PR8 (IPR8) in combination with experimental adjuvants that included flagellin (a TLR5 agonist) and R848 (a TLR7/8 agonist) (37-41). For delivery of these adjuvants, flagellin was mixed with IPR8 (IPR8+flg) while R848 was conjugated to the virus particle (IPR8-R848) as described in (42). We also evaluated the response generated in the presence of the combined adjuvants (IPR8-R848+flg). Vaccination with IPR8 plus an inactive flagellin (IPR8+m229) served as a non-adjuvanted control group and PBS administration served as a non-vaccinated control. Newborns received a boost dose 21 days following initial vaccination. Given our previous finding that the presence of flagellin, R848, or the combination of the two adjuvants could drive increased antibody responses and viral clearance (Table 1) (40,41), we anticipated that these adjuvants would result in higher NA-specific antibody.

Prior to assessing these responses, it was important to determine if there were enzymatically active NA in the vaccine. Activity would validate the structural integrity of the protein and thus support its potential to elicit antibodies whose recognition depended on an appropriate conformation. IPR8, IPR8-R848, heat inactivated (HI) PR8, and non-treated PR8 were assessed for NA activity by ELLA. While treatment with formalin considerably reduced NA activity, the activity was detectable, consistent with the presence of conformationally dependent epitopes that may be required for antibody recognition (SF1).

Antibody in the plasma was measured on d10 post boost (p.b.). Significantly elevated antibody titers to the PR8 virion resulting from the boost dose were present at this time (40,41). No antibody to NA was detected at this timepoint by either the cell based ELISA or ELLA approaches (Fig. 2). These data show that vaccination with IPR8, even in the presence of adjuvants that significantly boost the generation of total PR8-specific IgG antibodies, does not induce detectable NA-specific antibody at 10 days post-boost, a time at which infants had high levels of total PR8-specific IgG.

The presence of influenza-specific antibody generated in response to vaccination does not impact the level of systemic NA antibodies following challenge. Given the potential benefits of NAI antibodies in protecting against infection (43), we wanted to understand the effect of vaccine-elicited antibody (where antibody was directed to non-NA influenza virus proteins) on the generation of NA-specific antibody during infection. Vaccinated newborns were challenged with PR8 on day 23-26 following boost. Vaccinated and non-vaccinated (PBS) newborns did not have significantly different levels of circulating NA-specific IgG antibody (Fig. 3A) or NAI antibodies (Fig. 3B) at d14 p.c. The values from the two readouts for individual animals is shown in Figure 3C.

The similar level of NA-specific antibody generated across the groups is in contrast to the adjuvant associated increase in total influenza virus-specific IgG present in these animals

following challenge (Table 1) (40,41). Thus, while we cannot rule out the possibility that this antibody response arose from reactivation of vaccine induced, NA-specific memory B cells, we favor the hypothesis that this is a new response based on the similar levels of anti-NA antibody present in vaccinated and naïve (PBS) animals. Together, these data show pre-existing antibody to influenza virus proteins other than NA does not impact the circulating level of NA-specific antibody generated in newborns as a result of infection.

Vaccinated newborn AGM have lower respiratory NAI antibody 14 days following

infection compared to non-vaccinated animals. Effective neutralization and clearance of influenza virus is dependent on antibody in the respiratory tract. Thus, we evaluated NAI antibody responses in the lungs of vaccinated newborns at d14 following challenge. In contrast to what was observed in our analysis of systemic antibody at this timepoint, vaccinated infants had reduced levels of NAI antibody compared to non-vaccinated animals (Fig. 4A). We had initially prioritized analysis by ELLA because of limited sample. However, given the finding of reduced NAI antibody in the respiratory tract in the vaccinated groups, we performed an ELISA to quantify total NA-specific antibody. The trends were similar, although the decrease by the ELISA readout did not reach statistical significance (Fig. 4B). The values from the two readouts for the individual animals is shown in Figure 4C. This may suggest the ELISA assay is less precise for detecting the lower levels of antibody present in the BAL. Regardless, these data reveal variable NAI antibody responses in the lungs of infected infants that were previously vaccinated with IPR8, resulting in significantly reduced amounts across the group as a whole.

NA-specific antibodies do not emerge at later times in the vaccine response. In our evaluation, we had also administered our experimental vaccines to a group of newborns that were not challenged, i.e. the antibody response was allowed to develop over a longer period of time. We used this cohort to test whether the failure to detect NA-specific antibody in vaccinated

newborns at d10 p.b. was the result of assessment at a timepoint at which full maturation of the antibody response had not occurred. This could be the result of a difference in kinetics with regard to the differentiation of NA-specific activated B cells to antibody secreting cells compared to more dominant responses. The presence of NAI antibody was evaluated in newborns on approximately d100 following initial vaccination. Animals received the vaccine on the same schedule as those tested above. We found no evidence of NAI antibody at this timepoint (Fig. 5). As above an infected newborn served as a positive control for the detection of antibody. These data add further support to the inability of the vaccine to induce NA-specific antibody responses.

DISCUSSION

NA is emerging as an attractive target for influenza vaccines as antibodies against NA can be protective and often exhibit increased breadth of recognition across strains (13,14,17,18). While a clearer picture of this response is developing in adults, our understanding of the ability of newborns to generate NA-specific antibodies, following either infection or vaccination, is highly limited. Here we probed this question using a newborn NHP model. We found newborn animals make a robust antibody response to NA following infection and that these antibodies are highly capable of inhibiting enzymatic activity of the protein. In contrast, these responses were not detectable following vaccination with inactivated influenza virus, even in the presence of adjuvants that drive significantly higher total antibody responses to the virus (40,41). Circulating NAI antibodies were efficiently generated following virus challenge of the vaccinated newborns, reaching circulating levels that were similar to non-vaccinated newborns. However, while the systemic levels were similar, the presence of vaccine induced antibody responses was associated on average with reduced NAI antibodies in the respiratory tract compared to non-vaccinated animals.

The newborn response to influenza virus infection and vaccination has primarily been studied in the mouse model (e.g. (44-48)). Deficits have been reported in both the CD4⁺ and CD8⁺ T cell compartments (44,45) as well as the antibody response (47,48). In addition, there is some evidence that the B cell repertoire of newborns is altered (49-52), leaving open the possibility of a divergent ability to respond to the NA antigen. Thus, it was crucial that the inherent ability of newborns to mount an antibody response to NA be evaluated. We initially employed what is arguably the most potent immune challenge, viral infection, finding that newborns were highly competent for production of antibodies that can recognize NA and inhibit its enzymatic activity. This result is promising as previous human studies have demonstrated that NA-specific antibodies can contribute to protection (14). In addition to preventing the spread

of new virions to neighbouring cells, NA-specific antibodies can also facilitate clearance by promoting ADCC (53).

It was perhaps not unexpected that vaccination did not induce detectable NAI antibody. In humans, the inactivated influenza virus vaccine is inconsistent at driving NA-specific antibody responses (54,55). This is likely due, at least in part, to the failure to standardize NA content in vaccines and the lower level of NA compared to HA in the virion (56). With that said, we were a bit surprised that we did not detect NA-specific antibody in the newborns receiving the adjuvanted vaccines given the significant increase in total influenza virus-specific IgG in these animals (40,41). We acknowledge that we cannot rule out the possibility that some animals make low levels of antibody that were not detected in our analysis or did so transiently in a window that was not assessed.

Administration of the current seasonal inactivated vaccine would be anticipated to leave naive infants without measurable NA-specific antibodies, similar to what we observed in our nonhuman primate study. The effect of these non-NA, influenza-specific antibodies on the ability to generate an NA-specific response following infection is of significance given the potential benefit these antibodies can provide (13,14,17,18). We found that at d14 post infection, vaccinated newborn NHP had circulating levels of NAI antibodies that were similar to those observed for the non-vaccinated newborns. This result suggests any pre-existing influenza-specific antibody present as a result of vaccination did not impair the systemic NA-specific antibody response following homologous virus encounter. In contrast, there appears to be a regulatory effect of vaccine induced, pre-existing immunity on the local generation of NAI antibody in the respiratory tract of a significant portion of newborns. Interestingly, a decreased antibody response in the lung at d14 following infection was not evident in our analysis of total PR8-specific IgG (40,41), suggesting this may be specific to NA.

We propose the reduced NA-specific antibody present in the lungs of vaccinated infants following infection could result from an impaired ability of vaccine-induced memory B cells to

differentiate into antibody secreting cells or a reduced capacity to mount a primary NA-specific response. What might be responsible for a lung-specific effect? Local responses in the lung following infection with influenza virus are associated with the formation of bronchus associated lymphoid tissue (BALT) (57). Antigen acquisition in the BALT can occur via M cells if BALT forms near the epithelial surface or through DC migration into BALT that forms deeper in the tissue (58). How DCs are directed to the draining lymph node versus BALT is not clear; however, their migration could impact the access of B cells to antigen. It is also possible that virus particles or viral antigens travel more efficiently to the lymph node, again allowing larger amounts of antigen for binding to B cells. It does not appear that BALT has afferent lymphatics and as such viral antigen or antigen bearing cells that enter the afferent lymphatics may be more likely to reach the draining lymph node. It is possible that the requirements for efficiently eliciting the less dominant NA response are more stringent and thus changes in antigen load or innate signals that are present in the BALT versus the draining lymph node result in differential production of these antibodies.

In conclusion, we have shown newborn AGM generate antibodies that have NA inhibiting activity following influenza virus infection. This differs from the response to vaccination where antibody to NA could not be detected at either 10 days post boost or ~100 days following vaccination, even when adjuvants that significantly increased total influenza-specific IgG antibody were included in the vaccine (40,41). The presence of non-NA antibodies to influenza virus did not impact the level of circulating antibodies to NA generated as a result of infection; however, their presence was associated with a decrease in NA antibodies in the lungs of a substantial portion of newborns. While the results from these studies demonstrate the ability of newborns to generate NA-inhibiting antibodies, approaches designed to focus the response on this protein, e.g. increasing the dose of NA in current vaccines, use of recombinant proteins or NA expressing DNA vaccines, will be required to elicit robust levels of these antibodies that can contribute to protection.

METHODS

Animals. African green monkey newborns used in this study were housed at the Vervet Research Colony at Wake Forest School of Medicine. Vaccinated newborns were raised in a nursery setting (36,40,41). Non-vaccinated newborns infected with virus were mother reared. The WFSM animal care and use protocol adhered to the U.S. Animal Welfare Act and Regulations.

Influenza A/PR/8/34 (H1N1). A/Puerto Rico/8/34 (H1N1) (PR8) virus stock for infection was grown and titered in fertilized chicken eggs essentially as described previously (59). Stocks were diluted in PBS, flash frozen, and stored at -80°C.

Infection and sampling. Four adult African green monkeys (6–9 years old) were sedated with 10-15 mg/kg of ketamine. Four newborn animals (6–10 days old) were sedated with 2-5% inhalant isoflurane. Adults received 5×10^9 EID₅₀ PR8 by the combined intratracheal (i.t.) (1.0 ml) and intranasal (i.n.) (0.5 ml/nostril) routes. The dose was delivered equally between the intranasal (i.n.) and intratracheal (i.t.) routes. Three newborns were administered 1×10^9 EID₅₀ and one received 1×10^8 EID₅₀. (0.25 ml i.t. and 0.125 ml/nostril). No dose related difference was present in the newborn animal that received the lower versus higher dose. Thus these animals were pooled for the study. Blood was collected in sodium heparin tubes by venipuncture on d14 postinfection. BAL was performed at necropsy (d14p.i.) using 25ml for adults and 5 ml for infants. Samples were centrifuged to remove cellular material and BSA added to a final concentration of 0.5%.

Vaccination. Newborns were vaccinated with 45µg of 0.74% formaldehyde inactivated PR8 (IPR8) alone, IPR8 mixed 10µg of flagellin (flg), IPR8 conjugated to R848 (IPR8-R848), IPR8-

R848+flg, or IPR8 mixed with an inactive flagellin (m229) (60). All injections were delivered intramuscularly in the deltoid muscle (500µl volume). Animals were boosted 21 days later. Non-vaccinated control animals received PBS. The R848 conjugated virus was prepared as previously described (40). Briefly, an amine derivative of R848 (hereafter referred to as R848) was linked to SM(PEG)₄ by incubation in DMSO for 24h at 37°C. R848-SM(PEG)₄ was then incubated with influenza virus (IPR8-R848). Unconjugated R848 was removed by extensive dialysis, followed by inactivation with 0.74% formaldehyde overnight at 37°C. Formaldehyde was removed by dialysis. Successful conjugation was assessed by differential stimulation of RAW264.7 cells by R848 conjugated versus non-conjugated vaccine (42).

Flagellin from *Salmonella enteritidis* was prepared as previously described (60). Briefly, *E. coli* BL21 (DE3) containing a pet29a::*fliC* encoding wild type flagellin or the truncated pet29a::*229* encoding only the biologically inactive hypervariable region of flagellin (60,61) were grown and lysates prepared in 8M urea. Proteins were purified on Ni-NTA agarose (Qiagen) according to the manufacturer's protocol. Endotoxin and nucleic acids were removed using an Acrodisc Mustang Q capsule (Pall Corporation). Purified proteins were extensively dialyzed against PBS.

Enzyme Linked Lectin Assay (ELLA). Enzyme Linked Lectin Assay (ELLA). The Enzyme Linked Lectin Assay uses a reassortment H6N1 containing the HA (H6) gene from A/turkey/Massachusetts/3740/1965 and the internal protein gene segments and NA from A/Puerto Rico/8/1934 (PR8) (34). This virus was provided by Dr. Maryna Eichelberger, Center for Biologics Evaluation and Research, US Food and Drug Administration (Bethesda, MD). Virus was inactivated with beta-propiolactone, aliquoted and stored at -80°C. Prior to the assay, 96-well plates were coated overnight at 4°C with 100 µl of fetuin diluted in PBS (25 µg/ml). The next day, the plate was washed 3 times with PBS+0.05% Tween 20 (PBST). Plasma or BAL samples were heat inactivated (56°C for 45 minutes) and then serially diluted across the plate in

PBS+1% BSA+0.1% Tween 20. Inactivated virus was added at a dilution previously determined to result in 90% maximal NA activity and plates incubated at 37°C for 18hrs. Plates were washed 6 times with PBST and PNA-HRPO diluted in PBS+1% BSA (used at the highest dilution that gave the maximum signal when titrated on fully digested fetuin) added and incubated at RT for 1 hour. The plates were washed 3 times, developed with 3,3',5,5'-tetramethylbenzidine (Sigma) for 20 minutes, stopped with 2N H₂SO₄, and read at 450nm on a BioTek Elx800 Absorbance Microplate Reader. The starting dilution was 1:20 for plasma and 1:5 for BAL. The results were used to determine the 50% endpoint titer using the formula $100 \times (\text{OD}_{\text{virus only control}} - \text{OD}_{\text{test sample}}) / \text{OD}_{\text{virus only control}}$. Statistical analysis was performed using GraphPad Prism software on log₂ transformed values. Results that were below the limit of detection were assigned a value one dilution greater than the initial tested, e.g. if 1:20 was the initial dilution, values were assigned as 1:10) for graphing and statistical purposes.

Cell-Based NA ELISA. The ELISA is adapted from the protocol published by Wan et. al (33). Human embryonic kidney cells (293F, Gibco) cells grown to ~80% confluence in DMEM + Glutamax containing 7% FBS and were seeded into a 96-well round-bottom plate at 25,000 cells/well. Twenty-four hours later, cells were transfected with 0.2µg per well of PR8 NA expressing plasmid (pCAGGS-NA), generously provided by Dr. Jonathan Yewdell (NIH, Bethesda, MD), using Lipofectamine 2000 in FreeStyle 293 expression media with Glutamax (12338-018 Gibco). Cells were incubated for 5 hours at 37°C, media removed, and DMEM + Glutamax containing 7% FBS added. Cells were cultured for an additional 48 hours to allow expression of NA, after which cells were fixed with 0.05% glutaraldehyde and washed with PBS. As a control for successful transfection, a parallel culture was harvested and expression of NA confirmed by flow cytometric analysis following staining with a monoclonal anti-influenza A virus NA antibody (clone NA2-1C1,NR-50239, BEI Resources). The fixed plates were blocked with DMEM+ Glutamax + 7% FBS for 1 hour at 37°C. Samples were then added for 1 hour at 37°C

before being washed with PBST. Antibody was detected using anti-NHP IgG HRP (43R-IG020HRP, Fitzgerald). Plates were developed with TMB for 30 minutes and stopped with 2N H₂SO₄. Results that were below the limit of detection were assigned a value one dilution greater than the initial tested, e.g. if 1:20 was the initial dilution, values were assigned as 1:10) for graphing and statistical purposes.

Statistical analysis. Significance was determined using an unpaired two-tailed Student's t test or one-way ANOVA with Tukey correction for multiple comparisons as appropriate. All analyses were performed with Graphpad Prism software. A p value <0.05 was considered significant.

Study approval. All animal protocols were approved by the Institutional Animal Care and Use Committee of Wake Forest School of Medicine.

ACKNOWLEDGEMENTS

We thank members of the Alexander-Miller lab for helpful discussion of the manuscript. We thank Dr. Matt Jorgensen and the veterinary and care staff at the Vervet Research Colony. We acknowledge the kind gift of the PR8 NA expressing plasmid from Dr. Jonathan Yewdell and the collaboration with Dr. Maryna Eichelberger that allowed sharing the inactivated H6N1 virus preparation. This virus was generated using plasmids generously provided by St Jude Children's Hospital. Laura Couzens prepared the virus and provided helpful advice regarding the NA inhibition assay. We acknowledge BEI Resources for provision of the anti-NA antibody. These studies were supported by NIH R01 AI098339 (to M.A.A-M.) and a grant from the Wake Forest University Clinical and Translational Science Institute (UL1 TR001420). The Vervet Research Colony is supported in part by NIH P40 OD010965 (to M.J.J.).

Author Contributions: P.K.S. designed and performed experiments, analyzed data, and wrote the initial draft of the paper. K.F.C. performed experiments and analyzed data. B.C.H performed experiments. M.A.A-M. designed experiments edited the paper. All authors contributed to editing of the final manuscript.

REFERENCES

1. Cohen M, et al. Influenza a penetrates host mucus by cleaving sialic acids with neuraminidase. *Virology*. 2013; 10(1):321.
2. Yang C, Skiena S, Fitcher B, Mueller S, Wimmer E. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraproductive live vaccine in mice. *Proc Natl Acad Sci U S A*. 2013; 110(23):9481-9486.
3. Wagner R, Wolff T, Herwig A, Pleschka S, Klenk HD. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: A study by reverse genetics. *J Virol*. 2000; 74(14):6316-6323.
4. Yang X, et al. A beneficiary role for neuraminidase in influenza virus penetration through the respiratory mucus. *PLoS One*. 2014; 9(10):e110026.
5. Couch RB, et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. *J Infect Dis*. 2013; 207(6):974-981.
6. Ogra PL, et al. Clinical and immunologic evaluation of neuraminidase-specific influenza a virus vaccine in humans. *J Infect Dis*. 1977; 135(4):499-506.
7. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza a virus vaccine in children: Antibody responses and effects on two successive outbreaks of natural infection. *J Infect Dis*. 1979; 140(6):844-850.
8. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. *N Engl J Med*. 1972; 286(25):1329-1332.
9. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Jr., Ogra PL. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. *J Immunol*. 1987; 138(9):3010-3013.
10. Rajendran M, et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by elisa and enzyme inhibition: Evidence for original antigenic sin. *mBio*. 2017; 8(2):e02281-02216.
11. Monto AS, et al. Antibody to influenza virus neuraminidase: An independent correlate of protection. *J Infect Dis*. 2015; 212(8):1191-1199.
12. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. *J Infect Dis*. 1974; 129(4):411-420.
13. Wohlbold TJ, Krammer F. In the shadow of hemagglutinin: A growing interest in influenza viral neuraminidase and its role as a vaccine antigen. *Viruses*. 2014; 6(6):2465-2494.
14. Chen YQ, et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. *Cell*. 2018; 173(2):417-429
15. Harris A, et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. *Proc Natl Acad Sci U S A*. 2006; 103(50):19123-19127.
16. Padilla-Quirarte HO, Lopez-Guerrero DV, Gutierrez-Xicotencatl L, Esquivel-Guadarrama F. Protective antibodies against influenza proteins. *Front Immunol*. 2019; 10:1677.
17. Doyle TM, et al. Universal anti-neuraminidase antibody inhibiting all influenza a subtypes. *Antiviral Res*. 2013; 100(2):567-574.
18. Wohlbold TJ, et al. Broadly protective murine monoclonal antibodies against influenza b virus target highly conserved neuraminidase epitopes. *Nat Microbiol*. 2017; 2(10):1415-1424.
19. Poehling KA, et al. The underrecognized burden of influenza in young children. *N Engl J Med*. 2006; 355(1):31-40.
20. Munoz FM. Influenza virus infection in infancy and early childhood. *Paediatr Respir Rev*. 2003; 4(2):99-104.

21. Macdonald N, Bortolussi R. Protecting young babies from influenza. *Paediatr Child Health*. 2009; 14(9):612-617.
22. Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the united states, 2010–2016. *Pediatrics*. 2018; 141(4):e20172918.
23. Thompson MG, et al. Underdetection of laboratory-confirmed influenza-associated hospital admissions among infants: A multicentre, prospective study. *Lancet Child Adolesc Health*. 2019; 3(11):781-794.
24. Taubenberger JK, Morens DM. The pathology of influenza virus infections. *Annu Rev Pathol*. 2008; 3:499-522.
25. Groothuis JR, Levin MJ, Rabalais GP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. *Pediatrics*. 1991; 87(6):823-828.
26. Halasa NB, Gerber MA, Chen Q, Wright PF, Edwards KM. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. *J Infect Dis*. 2008; 197(10):1448-1454.
27. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. *Nat Rev Immunol*. 2004; 4(7):553-564.
28. Crowe JE, Jr., Williams JV. Immunology of viral respiratory tract infection in infancy. *Paediatr Respir Rev*. 2003; 4(2):112-119.
29. Saso A, Kampmann B. Vaccine responses in newborns. *Semin Immunopathol*. 2017; 39(6):627-642.
30. Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of the neonatal immune system. *Front Pediatr*. 2020; 8(5):5.
31. Fike AJ, Kumova OK, Carey AJ. Dissecting the defects in the neonatal cd8⁺ t-cell response. *J Leukoc Biol*. 2019; 106(5):1051-1061.
32. Debock I, Flamand V. Unbalanced neonatal cd4⁺ t-cell immunity. *Front Immunol*. 2014; 5(393):393.
33. Wan H, et al. Molecular basis for broad neuraminidase immunity: Conserved epitopes in seasonal and pandemic h1n1 as well as h5n1 influenza viruses. *J Virol*. 2013; 87(16):9290-9300.
34. Gao J, Couzens L, Eichelberger MC. Measuring influenza neuraminidase inhibition antibody titers by enzyme-linked lectin assay. *J Vis Exp*. 2016. 115:54573.
35. Gulati U, et al. Antibody epitopes on the neuraminidase of a recent h3n2 influenza virus (a/memphis/31/98). *J Virol*. 2002; 76(23):12274-12280.
36. Holbrook BC, et al. Nonhuman primate infants have an impaired respiratory but not systemic igg antibody response following influenza virus infection. *Virology*. 2015; 476:124-133.
37. Holbrook BC, et al. An r848 adjuvanted influenza vaccine promotes early activation of b cells in the draining lymph nodes of non-human primate neonates. *Immunology*. 2018; 153(3):357-367.
38. Holbrook BC, D'Agostino RB, Jr., Parks GD, Alexander-Miller MA. Adjuvanting an inactivated influenza vaccine with flagellin improves the function and quantity of the long-term antibody response in a nonhuman primate neonate model. *Vaccine*. 2016; 34(39):4712-4717.
39. Holbrook BC, et al. Adjuvanting an inactivated influenza vaccine with conjugated r848 improves the level of antibody present at 6months in a nonhuman primate neonate model. *Vaccine*. 2017; 35(45):6137-6142.
40. Holbrook BC, et al. A novel r848-conjugated inactivated influenza virus vaccine is efficacious and safe in a neonate nonhuman primate model. *J Immunol*. 2016; 197(2):555-564.
41. Kim JR, et al. Inclusion of flagellin during vaccination against influenza enhances recall responses in nonhuman primate neonates. *J Virol*. 2015; 89(14):7291-7303.

42. Westcott MM, Clemens EA, Holbrook BC, King SB, Alexander-Miller MA. The choice of linker for conjugating r848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells. *Vaccine*. 2018; 36(9):1174-1182.
43. Job ER, et al. Antibodies directed toward neuraminidase n1 control disease in a mouse model of influenza. *J Virol*. 2018; 92(4):e01584-01517.
44. You D, et al. Inchoate cd8+ t cell responses in neonatal mice permit influenza-induced persistent pulmonary dysfunction. *J Immunol*. 2008; 181(5):3486-3494.
45. Lines JL, Hoskins S, Hollifield M, Cauley LS, Garvy BA. The migration of t cells in response to influenza virus is altered in neonatal mice. *J Immunol*. 2010; 185(5):2980-2988.
46. Wolf AI, et al. Protective antiviral antibody responses in a mouse model of influenza virus infection require taci. *J Clin Invest*. 2011; 121(10):3954-3964.
47. Sherman MP, Pritzl CJ, Xia C, Miller MM, Zaghouani H, Hahm B. Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice. *Biochem Biophys Res Commun*. 2015; 467(4):766-770.
48. McDonald JU, Zhong Z, Groves HT, Tregoning JS. Inflammatory responses to influenza vaccination at the extremes of age. *Immunology*. 2017; 151(4):451-463.
49. Williams JV, Weitkamp JH, Blum DL, LaFleur BJ, Crowe JE, Jr. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. *Mol Immunol*. 2009; 47(2-3):407-414.
50. Sun J, Butler JE. Molecular characterization of vdj transcripts from a newborn piglet. *Immunology*. 1996; 88(3):331-339.
51. Hong B, et al. In-depth analysis of human neonatal and adult igm antibody repertoires. *Front Immunol*. 2018; 9:128.
52. Shiokawa S, et al. Igm heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. *J Immunol*. 1999; 162(10):6060-6070.
53. Jegaskanda S, Co MDT, Cruz J, Subbarao K, Ennis FA, Terajima M. Induction of h7n9-cross-reactive antibody-dependent cellular cytotoxicity antibodies by human seasonal influenza a viruses that are directed toward the nucleoprotein. *J Infect Dis*. 2017; 215(5):818-823.
54. Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. *Nature*. 2008; 453(7195):667-671.
55. Couch RB, et al. Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. *Vaccine*. 2012; 31(1):190-195.
56. Gerentes L, Kessler N, Aymard M. Difficulties in standardizing the neuraminidase content of influenza vaccines. *Dev Biol Stand*. 1999; 98:189-196.
57. Moyron-Quiroz JE, et al. Role of inducible bronchus associated lymphoid tissue (ibalt) in respiratory immunity. *Nat Med*. 2004; 10(9):927-934.
58. Randall TD. Structure, organization, and development of the mucosal immune system of the respiratory tract. *Mucosal Immunol*. 2015:43-61.
59. Klimov A, et al. Influenza virus titration, antigenic characterization, and serological methods for antibody detection. *Methods Mol Biol*. 2012; 865:25-51.
60. McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. *Infect Immun*. 2000; 68(10):5525-5529.
61. Honko AN, Mizel SB. Mucosal administration of flagellin induces innate immunity in the mouse lung. *Infect Immun*. 2004; 72(11):6676-6679.

Table 1. Total PR8-specific IgG induced by vaccination and viral load d5 following challenge.

PBS		IPR8+m229		IPR8+flg		IPR8-R848		IPR8-R848+flg	
Total IgG ^{1,2}	Virus load ^{2,3}	Total IgG	Virus load	Total IgG	Virus load	Total IgG	Virus load	Total IgG	Virus load
BLD	4.9e6	12800	BLD	12800	9.8e4	102400	7.3e3	102400	BLD
BLD	1.3e6	6400	BLD	3200	9.8e3	204800	BLD	51200	BLD
BLD	1.7e5	3200	9.6e5	3200	1.9e5	12800	8.2e4	51200	BLD
		800	1.3e8	12800	BLD	6400	4.6e8	102400	BLD
		12800	2.5e5	6400	3.2e5	51200	BLD	6400	3.1e4
				6400	6.0e5	25600	BLD	25600	BLD
						6400	BLD	102400	BLD

¹Threshold titer for anti-influenza virus IgG in plasma at d21 following boost.

²The total IgG and viral titer (EID₅₀ equivalents) on d5 p.c. Data were originally published in *The Journal of Immunology*. Holbrook, B.C., J.R. Kim, L.K. Blevins, M.J. Jorgensen, N.D. Kock, R. D'Agostino Jr, S.T. Aycock, M.B. Hadimani, S.B. King, G.D. Parks, and M.A. Alexander-Miller. 2016. A novel R848-conjugated inactivated influenza virus vaccine is efficacious and safe in a neonate nonhuman primate model. *J. Immunol.* 197:555-64. Copyright © 2016 The American Association of Immunologists, Inc. (40) or in *The Journal of Virology*. Kim J.R., B.C. Holbrook, S.L. Hayward, L.K. Blevins, M.J. Jorgensen, N.D. Kock, K. De Paris, R. D'Agostino Jr, S.T. Aycock, S.B. Mizel, G.D. Parks, and M.A. Alexander-Miller. 2015 Inclusion of flagellin during vaccination against influenza enhances recall responses in nonhuman primate neonates. *J. Virol.* 89:7291-303. Copyright © 2015 The American Society for Microbiology (41).

³ Virus load for animals that underwent challenge is shown. A dash indicates these animals were not challenged.

BLD: below limit of detection




Figure 1. Infant AGM generate NA-specific antibodies with inhibitory activity following infection with influenza virus. Infant (6-10 days of age) and adult AGM (6-9 years of age) were infected with PR8 (n=4/group). The presence of total NA-specific IgG (A) and NA inhibiting antibody (B) was assessed at d14 p.i. (C) ELLA and ELISA values for antibody in plasma from individual animals are shown. Total NA-specific IgG (D) and NA inhibiting antibody (E) in the BAL were also measured. (F) ELLA and ELISA values for antibody in BAL from individual animals are shown. Pre-infection samples for the adult animals used in the study are shown. The naïve newborn data were obtained from a separate cohort of age matched animals as we did not have pre-infection samples available for testing. The dotted line shows the limit of detection (LOD) for the assay. Significance was assessed using an unpaired Student's t test.




Figure 2. NA-specific antibodies are not detected in vaccinated infants at d10 post boost.

Newborn AGM were vaccinated with IPR8+m229, IPR8+flg, IPR8-R848, or IPR8-R848+flg or received PBS. Newborns were boosted 21 days following initial vaccination. Plasma was evaluated at d10 post boost by ELISA for measurement of total NA-specific IgG (A) or ELLA to quantify NA inhibiting antibody (B). The analysis included newborns vaccinated with IPR8+m229 (n=5), IPR8+flg (n=6), IPR8-R848 (n=7) or IPR8-R848+flg (n=7). Three animals were in the control group that received PBS. The data from an infected newborn run in parallel with the assay is shown as a positive control. The dotted line shows the limit of detection (LOD) for the assay. Statistical analysis was performed using one-way ANOVA with Tukey correction for multiple comparisons.




Figure 3. Vaccine elicited antibody does not affect the level of NA-specific antibody generated following viral challenge. Vaccinated newborn AGM were challenged with PR8 at day 23-26 following boost. Plasma was tested on d14 p.c. using (A) ELISA to measure NA-specific IgG or (B) ELLA to measure NA neutralizing antibody. The dotted line shows the LOD for the assay. Statistical analysis was performed using one-way ANOVA with Tukey correction for multiple comparisons.




Figure 4. A portion of vaccinated newborns generate neutralizing antibody to NA in the respiratory tract after viral challenge. BAL samples were assessed 14 days p.c for NAI activity (A) and NA-specific IgG (B). Data from each readout for individual animals is shown in (C). The dotted line shows the LOD for the assay. Statistical analysis was performed using one-way ANOVA with Tukey correction for multiple comparisons. * $p < 0.05$, ** $p < 0.005$





Figure 5. The inclusion of adjuvants that boost the overall response to PR8 does not induce detectable NA-specific antibodies at d100 following vaccination. Vaccinated and non-vaccinated newborn AGM were evaluated by ELLA at approximately d100 following vaccination. The analysis included newborns vaccinated with IPR8+m229 (n=5), IPR8+flg (n=6), IPR8-R848 (n=7) or IPR8-R848+flg (n=7). Two animals were in the control group that received PBS. The data from an infected newborn run in parallel with the assay is shown as the positive control. The dotted line shows the limit of detection (LOD) for the assay. Statistical analysis was performed using one-way ANOVA with Tukey correction for multiple comparisons.



SF1. Formalin inactivated PR8 has reduced NA activity compared to live PR8. PR8, IPR8, IPR8-R848, and heat treated PR8 were tested for the level of NA activity using the ELLA assay. Heat inactivation was performed by placing virus at 56°C for 1 hour.